Talk about the Ireland fully furnished PO box as much as you like. That's the only thing you are capable to discuss anyway. So please, go ahead, the craic is going to be mighty.
The list of your well researched posts stock proven to be incorrect and misleading is long. Another few additional ones to add to your CV wont hurt your "rep." As I said before, you've been shown to not have a clue about a stocl you are financially invested in, therefore not exactly expectong miracles for a stock you are only emotionally invested in. As they say, if it walks like a clown, talks like a clown...
Britannica:
may
/ˈmeɪ/
verb
[modal verb]
1
— used to indicate that something is possible or probable
[+] Example sentences
2
— used to say that one thing is true but something else is also true
[+] Example sentences
3
formal — used to indicate that something is allowed
[+] Example sentences
— compare can 4b
4
formal — used to ask a question or make a request in a polite way
[+] Example sentences
— compare can 4a
5
formal — used to express a wish
[+] Example sentences
6
formal — used to make a polite suggestion
[+] Example sentences
7
formal — used in various polite expressions with I
[+] Example sentences
8
formal + old-fashioned — used to indicate the reason for something or the purpose of something
[+] Example sentences
Simpleton picks the definition that suits the simpleton agenda. And keeps repeating it, hoping his version becomes a HC fact, like a mailbox being a holiday home.
Please tell us more about this office in Ireland. Go ahead. I'm not stopping you.
You want an FDA statement that approval after a Phase 2 MAY be possible, actually, IS possible, actually, HAS ALREADY HAPPENED, in cGvHD:
FDA approves belumosudil for chronic graft-versus-host disease
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belumosudil-chronic-graft-versus-host-diseaseTo make it a bit clearer also for TipRankGPT and the other bottom feeder:
"The approval was supported by data from the phase 2 AGAVE-201 study (ClinicalTrials.gov Identifier: NCT04710576), which evaluated the safety and efficacy of axatilimab in 79 adult and pediatric patients with recurrent or refractory active GVHD whose disease had progressed after 2 therapies."
https://www.gastroenterologyadvisor.com/news/fda-approves-new-vial-sizes-for-gvhd-treatment-niktimvo/#:~:text=The%20approval%20was%20supported%20by,had%20progressed%20after%202%20therapies.
I'm sure everyone is shocked finding you again here on our stage with your pants dropped down to your ankles.
(20min delay)